Management and Treatment of Recurrent Epithelial Ovarian Cancer

被引：45

作者：

Armbruster, Shannon ^{[1
]}

Coleman, Robert L. ^{[1
]}

Rauh-Hain, Jose Alejandro ^{[1
,2
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol & Reprod Med, Unit 1362, 1155 Herman Pressler, Houston, TX 77030 USA

[2] Univ Texas MD Anderson Canc Ctr, Dept Hlth Serv Res, Unit 1444, 1515 Holcombe Blvd,POB 301402, Houston, TX 77230 USA

来源：

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2018年 / 32卷 / 06期

关键词：

Ovarian cancer; Recurrence; PARP; Immunotherapy; Chemotherapy; Secondary cytoreduction; PLATINUM-RESISTANT OVARIAN; PEGYLATED LIPOSOMAL DOXORUBICIN; SECONDARY CYTOREDUCTIVE SURGERY; CONTROLLED PHASE-III; DOUBLE-BLIND; OPEN-LABEL; MAINTENANCE THERAPY; PRIMARY PERITONEAL; TUMOR ANGIOGENESIS; ANTITUMOR-ACTIVITY;

D O I：

10.1016/j.hoc.2018.07.005

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Most women with advanced epithelial ovarian cancer will experience many episodes of recurrent disease with progressively shorter disease-free intervals. For women whose disease continues to respond to platinum based drugs, the disease can often be controlled for 5 years or more. Enormous progress has been made in the management of this disease, and new targeted treatments such as antiangiogenic drugs, poly(adenosine diphosphate-ribose) polymerase inhibitors, and immune checkpoint inhibitors offer potential for improved survival. A variety of combination strategies are being evaluated to leverage these agents. The role of secondary cytoreduction remains a topic of active investigation.

引用

页码：965 / +

页数：19

共 70 条

[1] Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer [J].

Aghajanian, Carol ;

Goff, Barbara ;

Nycum, Lawrence R. ;

Wang, Yan V. ;

Husain, Amreen ;

Blank, Stephanie V. .

GYNECOLOGIC ONCOLOGY, 2015, 139 (01) :10-16

[2] OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer [J].

Aghajanian, Carol ;

Blank, Stephanie V. ;

Goff, Barbara A. ;

Judson, Patricia L. ;

Teneriello, Michael G. ;

Husain, Amreen ;

Sovak, Mika A. ;

Yi, Jing ;

Nycum, Lawrence R. .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (17) :2039-2045

[3]

Alvarez AA, 1999, CLIN CANCER RES, V5, P587

[4]

[Anonymous], 49 ANN M SOC GYN ONC

[5]

[Anonymous], 49 ANN M SOC GYN ONC

[6]

[Anonymous], 2014, LANCET, DOI DOI 10.1016/S0140-6736(13)62146-7

[7]

[Anonymous], J CLIN ONCOL

[8]

[Anonymous], ANN ONCOL S8

[9]

[Anonymous], ASCO M

[10] Integrated genomic analyses of ovarian carcinoma [J].

Bell, D. ;

Berchuck, A. ;

Birrer, M. ;

Chien, J. ;

Cramer, D. W. ;

Dao, F. ;

Dhir, R. ;

DiSaia, P. ;

Gabra, H. ;

Glenn, P. ;

Godwin, A. K. ;

Gross, J. ;

Hartmann, L. ;

Huang, M. ;

Huntsman, D. G. ;

Iacocca, M. ;

Imielinski, M. ;

Kalloger, S. ;

Karlan, B. Y. ;

Levine, D. A. ;

Mills, G. B. ;

Morrison, C. ;

Mutch, D. ;

Olvera, N. ;

Orsulic, S. ;

Park, K. ;

Petrelli, N. ;

Rabeno, B. ;

Rader, J. S. ;

Sikic, B. I. ;

Smith-McCune, K. ;

Sood, A. K. ;

Bowtell, D. ;

Penny, R. ;

Testa, J. R. ;

Chang, K. ;

Dinh, H. H. ;

Drummond, J. A. ;

Fowler, G. ;

Gunaratne, P. ;

Hawes, A. C. ;

Kovar, C. L. ;

Lewis, L. R. ;

Morgan, M. B. ;

Newsham, I. F. ;

Santibanez, J. ;

Reid, J. G. ;

Trevino, L. R. ;

Wu, Y. -Q. ;

Wang, M. .

NATURE, 2011, 474 (7353) :609-615

← 1 2 3 4 5 6 7 →